Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 88Neoplasm Metastasis 4HER2-positive Breast Cancer 4Stomach Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Esophageal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants 1Thyroid Neoplasms 1Thrombocytosis 1Sarcoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Preference 1Pathologic Complete Response 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Metastatic HER2-positive Breast Cancer With Brain Metastasis 1

Interventions

spartalizumab 2durvalumab 2zanidatamab 1tremelimumab 1trastuzumab deruxtecan 1tislelizumab 1pembrolizumab 1obinutuzumab 1naptumomab estafenatox 1Trastuzumab 1Polymerase Chain Reaction 1Nivolumab 1Mass Spectrometry 1In Situ Hybridization, Fluorescence 1Immunohistochemistry 1Gemcitabine 1Capecitabine 1Albumin-Bound Paclitaxel 1Ado-Trastuzumab Emtansine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Ado-Trastuzumab Emtansine × Breast × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡